CARA vs. CYBN, SCPH, RGLS, CTMX, RPTX, GOSS, CRVS, SYRS, OPTN, and ACET
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Cybin (CYBN), scPharmaceuticals (SCPH), Regulus Therapeutics (RGLS), CytomX Therapeutics (CTMX), Repare Therapeutics (RPTX), Gossamer Bio (GOSS), Corvus Pharmaceuticals (CRVS), Syros Pharmaceuticals (SYRS), OptiNose (OPTN), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Cara Therapeutics (NASDAQ:CARA) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking.
Cara Therapeutics received 666 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 75.03% of users gave Cara Therapeutics an outperform vote.
Cara Therapeutics presently has a consensus target price of $11.12, indicating a potential upside of 1,612.35%. Cybin has a consensus target price of $5.00, indicating a potential upside of 1,328.57%. Given Cara Therapeutics' higher probable upside, research analysts plainly believe Cara Therapeutics is more favorable than Cybin.
44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Cara Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.
Cybin has a net margin of 0.00% compared to Cara Therapeutics' net margin of -723.49%. Cybin's return on equity of -109.05% beat Cara Therapeutics' return on equity.
Cybin has lower revenue, but higher earnings than Cara Therapeutics. Cybin is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cara Therapeutics had 5 more articles in the media than Cybin. MarketBeat recorded 6 mentions for Cara Therapeutics and 1 mentions for Cybin. Cara Therapeutics' average media sentiment score of 0.76 beat Cybin's score of 0.00 indicating that Cara Therapeutics is being referred to more favorably in the media.
Summary
Cara Therapeutics beats Cybin on 9 of the 17 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
